Hepion Pharmaceuticals, Inc.

DB:336 Stock Report

Market Cap: €26.5m

Hepion Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 336?
Owner TypeNumber of SharesOwnership Percentage
Private Companies5280.0139%
Individual Insiders5,5810.146%
Institutions370,2379.71%
General Public3,435,13690.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 9.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.34%
The Vanguard Group, Inc.
165,509€1.1m0%no data
2.1%
BlackRock, Inc.
80,138€556.1k0.33%no data
0.86%
Geode Capital Management, LLC
32,822€227.8k0%no data
0.83%
Charles Schwab Investment Management, Inc.
31,535€218.8k1,900%no data
0.41%
State Street Global Advisors, Inc.
15,675€108.8k0%no data
0.37%
Renaissance Technologies LLC
14,215€98.6k15.8%no data
0.2%
Susquehanna International Group, LLP, Asset Management Arm
7,737€53.7k61.3%no data
0.17%
Northern Trust Global Investments
6,602€45.8k0%no data
0.12%
Morgan Stanley & Co. International Plc Investment Account
4,410€30.6k9.7%no data
0.075%
PNC Financial Services Group Inc., Banking Investments
2,876€20.0k-0.07%no data
0.062%
Robert Foster
2,364€16.4k0%no data
0.059%
Vision2020 Wealth Management Corp.
2,263€15.7k44%no data
0.039%
Petrus L. Wijngaard
1,501€10.4k0%no data
0.034%
Two Sigma Advisers, LP
1,295€9.0k0%no data
0.028%
Gesiuris, SA
1,067€7.4k0%no data
0.026%
Cetera Investment Advisers LLC
987€6.9k-33.6%no data
0.02%
John Cavan
747€5.2k0%no data
0.018%
UBS Asset Management AG
703€4.9k0%no data
0.017%
Amussen, Hunsaker & Associates, LLC
665€4.6k0%no data
0.017%
Group One Trading LP, Asset Management Arm
656€4.6k-46%no data
0.016%
Gary Jacob
610€4.2k0%no data
0.015%
Lord, Abbett & Co. LLC
578€4.0k0%no data
0.014%
Tower Research Capital LLC
528€3.7k-67.3%no data
0.011%
Victory Capital Management Inc.
426€3.0k0%no data
0.0092%
John Brancaccio
352€2.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/08 06:33
End of Day Share Price 2023/05/12 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hepion Pharmaceuticals, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Kumaraguru RajaBrookline Capital Markets
Kristen KluskaCantor Fitzgerald & Co.